MetaCap

Vir Biotechnology Inc. (VIR)

NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

8.39-0.48 (-5.41%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VIR stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.18
52-week range
5.45 – 14.38
Day range
8.34 – 8.92
Volume / Avg
3.09M / 2.45M
Beta
—

52-week range

$5.45$14.38

VIR stock today

On Nov 20, VIR ended the session at $8.39, shedding $0.48 (5.41%), versus the S&P 500's 3.70% decline. Shares are 41.7% below their 52-week high of $14.38, set on Nov 9, 2026 and 53.9% above the 52-week low of $5.45, in the middle of the past year's range. VIR is up 39.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 47.7%.

Vir Biotechnology has posted a net loss over the last twelve months (EPS of -$1.18), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Vir Biotechnology

Company profile

Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Headquarters
San Francisco, CA
Employees
367
IPO year
2019
Website
vir.bio

Financial highlights

Full financials

In fiscal 2025, Vir Biotechnology generated $68.6 million in revenue, down 7.6% from fiscal 2024, its first annual decline since 2024. Vir Biotechnology reported a net loss of $438.0 million, compared with a loss of $522.0 million a year earlier. Gross margin was 100.0% (up from 98.9%) and operating margin -699.2%.

Vir Biotechnology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$68.56M$74.20M$86.18M$1.62B$1.10B
Growth-7.61%-13.90%-94.67%+47.51%+1334.39%
Net income$-437.99M$-521.96M$-615.06M$515.84M$528.58M
EPS (diluted)$-3.16$-3.83$-4.59$3.83$3.96

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$23.38+178.67%

  • Strong buy 3
  • Buy 5
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $17.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.57 vs $-0.80
Surprise
+28.75%

VIR news

All VIR news

Vir Biotechnology peers

Health Care sector
VIR peer companies
CompanyPrice% ChgMarket capCompare
RXRXRecursion Pharmaceuticals Inc. Class A2.45-9.93%$1.53Bvs VIR
ALVOAlvotech4.12-3.96%$1.47Bvs VIR
WWBWindward Bio Group AG24.29+1.15%$1.45Bvs VIR
MESOMesoblast Limited ADR10.89-2.59%$1.41Bvs VIR
MAZEMaze Therapeutics Inc.31.37-3.27%$1.72Bvs VIR
LYCALycia Therapeutics Inc.33.07+4.09%$1.72Bvs VIR
IMCRImmunocore Holdings plc ADR26.41-0.83%$1.36Bvs VIR
REPLReplimune Group Inc.19.07-0.83%$1.81Bvs VIR

Indexes, lists and sector

Vir Biotechnology stock FAQ

What is Vir Biotechnology's stock price today?

VIR last traded at $8.39 as of Nov 20, 4:00 PM EST, down 5.41% on the day. Prices are delayed at least 15 minutes.

Who is Vir Biotechnology's CEO?

Dr. Marianne De Backer M.B.A., M.Sc., Ph.D. is the chief executive officer of Vir Biotechnology Inc., which has about 367 employees.

What is the VIR 52-week high?

The 52-week high for VIR is $14.38 and the 52-week low is $5.45. The stock is currently 41.7% below its high.

Compare VIR